Table 1.
Baseline patient characteristics
| Baseline demographics | n (%) (N=498) |
| Age (years) | 67.4±16.1 |
| Male | 310 (62.2) |
| Weight (kg) (n=294) | 80.1±21.1 |
| BMI (kg/m2) (n=263) | 28.3±7.0 |
| Comorbidities | |
| Hypertension | 266 (53.4) |
| Dyslipidaemia | 158 (31.7) |
| Diabetes | 200 (40.2) |
| Diet controlled | 40 (20) |
| Tablets | 103 (51.5) |
| Insulin | 57 (28.5) |
| COPD | 34 (6.8) |
| Asthma | 45 (9.0) |
| Chronic kidney disease | 98 (19.7) |
| ESRF on dialysis | 37 (7.4) |
| Coronary artery disease | 69 (13.9) |
| Previous MI | 45 (9.0) |
| Previous CABG | 11 (2.2) |
| Atrial fibrillation | 65 (13.1) |
| Previous PCI | 27 (5.4) |
| LV impairment | 33 (6.6) |
| Previous CVA | 59 (11.8) |
| Smoking status | |
| Non | 457 (91.8) |
| Current | 12 (2.4) |
| Ex-smoker | 29 (5.8) |
| Admission medication | |
| Aspirin | 88 (17.7) |
| Anticoagulation | 58 (11.6) |
| ACE Inhibitor | 100 (20.1) |
| Angiotensin receptor blocker | 52 (10.4) |
| Paracetamol | 95 (19.1) |
| NSAIDs | 10 (2) |
| Statin | 211 (42.4) |
BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ESRF, end-stage renal failure; LV, left ventricular; MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory drug; PCI, percutaneous coronary intervention.